23andMe

23andMe inches closer to cancer immunotherapy, guided by its genetic database. Dr. Jennifer Low, head of 23andMe’s therapeutics division, talks about the development of oncology checkpoint inhibitors that target a unique pathway. https://lnkd.in/g5Efvfhk

Yesterday we announced the launch of a new large-scale study to identify genetic and non-genetic associations with the weight loss variation and side effects experienced by people that take GLP-1 medications. We are hopeful that by exploring this field further, we can leverage the data uncovered to influence future personalized weight loss treatment options for varied individuals. For more information on the study, please visit: https://23and.me/4ciJ4gj

The National Association of Black Journalists (NABJ) and its members play a crucial role in informing and empowering communities through their reporting. We were honored to be a sponsor of last week's #NABJConvention to engage with these journalists in conversations around health and science and wellness. #NABJ2024

Attending the National Medical Association Annual Convention and Scientific Assembly in NYC this week? Visit us at booth #209 to learn more about how we’re helping people identify their genetic risks and take action. Plus, hear from our collaborator AfroPink,Inc about the ways we partner with community-based advocacy organizations to promote genetics-informed screening and prevention!

Have you heard the news? The award-winning musical Our Little Secret - a completely true story of Noam Tomaschoff's discovery that he wasn't an only child and how he learned through a 23andMe test that he had more than 35 siblings globally - is now showing at the biggest arts festival in the world, Edinburgh Fringe! It's running nightly at 5:30 PM at the Gilded Balloon Patter Hoose - Doonstairs, make sure to stop by if you're in town! https://lnkd.in/gfWWkPma

Last week, we joined 20 advocacy organizations to launch the Lung Cancer Genetics Study. With this study, we hope to learn more about the genetics behind the disease to transform our understanding of risk and treatment. Learn more here: https://23and.me/4dnvw47

Today we’re announcing a new study to advance research on lung cancer. While lung cancer research and targeted therapies have provided hope and progress for many, this study aims to learn more about the genetics behind the disease and its causes. Learn more here: https://23and.me/3zVjzEm

Powerful New York Magazine article on genetic testing for Alzheimer’s disease risk. We celebrate giving access to those who want to know their genetic risk. Genetic testing is a choice we believe gives people agency over their health and facilitates personalized prevention as early as possible. #prevention #genetics #alzheimers https://lnkd.in/gbzDyHs6

Our latest Breast, Prostate and Colorectal Cancer polygenic risk score (PRS) reports* work together with our other reports on these conditions to provide 23andMe+® Premium members new insights into their genetic likelihood of developing three of the most common cancers. With these reports and more, you can assess your likelihood and take action through personalized next steps. *Breast Cancer report (females only), Prostate Cancer report (males only) and Colorectal Cancer report (certain ethnicities). The 23andMe Breast, Prostate and Colorectal PRS reports are based on genetic model that include data and insights from 23andMe consented research participants and incorporate thousands of genetic variants to describe if a person has a certain likelihood of developing a condition, but does not describe a person’s overall likelihood. The PRS reports do not account for lifestyle or family history and have not been reviewed by the FDA. The PRS reports are not intended to tell you anything about your current state of health, or to be used to make medical decisions or determine any treatment.

In early July, President Biden signed into law the National Plan to End Parkinson's Act. Seeing this bipartisan legislation become law is heartening, as it will bolster efforts to find new treatments and ultimately cure Parkinson's. 23andMe launched our Parkinson's Research effort 15 years ago, leveraging our unique research model to aid in the fight against this disease. More than 33,000 people with Parkinson's are now part of our Parkinson's Research community. That community and the millions of 23andMe customers who have consented to participate in our research make this work possible. Together, we've published over two dozen papers. Collaborating with the Michael J. Fox Foundation and the Parkinson's Foundation, among others, we hope to make progress towards our goal of ending Parkinson’s.